Skip to content

The effect of cell therapy for knee joint osteoarthritis using angiography

Phase III Clinical Trial Investigating the Efficacy of Intravascular Mesenchymal Stem Cell Injections for Knee Joint Osteoarthritis

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20140818018842N43
Enrollment
140
Registered
2024-12-16
Start date
2024-09-08
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee arthrosis. Primary osteoarthritis of other joints

Interventions

Intervention 1: Intervention Group: For this purpose, 140 patients with OA, with an average age of 40 years, will be selected. To inject mesenchymal cells, the following steps are performed: puncturin

Sponsors

Motamed Cancer Institute
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Symptomatic OA knee: This includes individuals who experience daily pain that has started at least3 months prior to their visit. Patients should fall within grades1-3 of the Lawrence-Kellgren criteria. (The reason for using this range of grades in the Lawrence-Kellgren classification is that similar studies in cell therapy mostly begin with mild stages. This is because the application of cell therapy in diseases shows increased accuracy, as in advanced stages of the disease, the likelihood of minor effectiveness being overlooked is very high due to the progression of disease severity.) Radiographic changes in the specified knee should be observed without meniscus tears.

Exclusion criteria

Exclusion criteria: Generalized bone marrow edema in the condyle or tibia on MRI Moris deformity (varus or valgus) more than10 Hyaluronic acid use in the knee during the past6 months Intra-articular steroid use in the past6 months Oral steroid use in the past3 months Simultaneous pain in the ankle or hip on the same side Local or systemic infection Any manifestation of secondary arthritis Recent history of malignancy BMI greater than30 Autoimmune diseases

Design outcomes

Primary

MeasureTime frame
Pain reduction score in the questionnaire. Timepoint: Multiple time intervals of 1, 3, 6, 9, and 12 weeks after the intervention. Method of measurement: Western Ontario and McMaster Universities Arthritis Index and Visual Analogue Scale.;Evaluation of cartilage thickness and health in different parts of the knee. Timepoint: 12 months after the intervention. Method of measurement: Magnetic resonance imaging(MRI).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Ghenaati

Tehran University of Medical Sciences

ghanaati@yahoo.com+98 21 6658 1577

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026